Syndax Pharmaceuticals (SNDX) Stock Statistics & Valuation Metrics

Syndax Pharmaceuticals has a market cap or net worth of $1.03B. The enterprise value is $907.01M.

Syndax Pharmaceuticals has 86,044,030 shares outstanding. The number of shares has decreased by -2.65% in one year.

Syndax Pharmaceuticals’s return on equity (ROE) is -1.11 and return on invested capital (ROIC) is -53.59%.

The current PE Ratio of Syndax Pharmaceuticals is -3.54. Syndax Pharmaceuticals’s PEG ratio is -0.14.

In the last 12 months, Syndax Pharmaceuticals had revenue of 23.68M and earned -318.76M in profits. Earnings per share was -3.73.

In the last 12 months, operating cash flow was -274.90M and capital expenditures 0.00, giving a free cash flow of -274.90M billion.

Syndax Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Syndax Pharmaceuticals upcoming earnings date is May 12, 2025, TBA Not Confirmed.

Syndax Pharmaceuticals as a current ratio of 5.82, with Debt / Equity ratio of 120.00%

In the past 12 months, Syndax Pharmaceuticals has paid 0.00 in taxes.

Syndax Pharmaceuticals EV to EBITDA ratio is -3.15, with an EV/FCF ratio of -3.59.

Syndax Pharmaceuticals has $582.91M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$237.17M billion.

Gross margin is -87.26%, with operating margin of -1434.43%, and net profit margin of -1346.11%.

The average price target for Syndax Pharmaceuticals is $34.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy